Literature DB >> 20840327

Emphysematous pyelonephritis.

Sarvpreet Singh Ubee1, Laura McGlynn, Mark Fordham.   

Abstract

Emphysematous pyelonephritis (EPN) is a severe necrotizing infection of the renal parenchyma. The clinical course of EPN can be severe and life-threatening if not recognized and treated promptly. Most of the information has been from case reports, a few large series have also been reported. Using an evidence-based approach, this review describes the pathogenesis, classification, complications, and management of EPN. Emphysematous pyelonephritis (EPN) is an acute severe necrotizing infection of the renal parenchyma and its surrounding tissues that results in the presence of gas in the renal parenchyma, collecting system, or perinephric tissue. The cause for mortality in EPN is primarily due to septic complications. Up to 95% of the cases with EPN have underlying uncontrolled diabetes mellitus. The risk of developing EPN secondary to a urinary tract obstruction is about 25-40%. There are three classifications of EPN based on radiological findings. Acute renal failure, microscopic or macroscopic haematuria, severe proteinuria are other positive findings in EPN. Escherichia coli is the most common causative pathogen with the organism isolated on urine or pus cultures in nearly 70% of the reported cases. A plain radiograph shows an abnormal gas shadow in the renal bed raising the suspicion whereas an ultrasound scan or computed tomography (CT) will confirm the presence of intra-renal gas thus supporting the diagnosis of EPN. Gas may extend beyond the site of inflammation to the sub capsular, perinephric and pararenal spaces. In some cases, gas was found to be extending into the scrotal sac and spermatic cord. Subsequent case studies have shown patients being successfully treated with PCD when used in addition to medical management, with significant reduction in the morality rates. PCD should be performed on patients who have localized areas of gas and functioning renal tissue is present. The treatment strategies include MM alone, PCD plus MM, MM plus emergency nephrectomy, and PCD plus MM plus emergency nephrectomy. In small proportion of patients managed with MM and PCD, subsequent nephrectomy will be required and in these patients the reported mortality is 6.6% Nephrectomy in patients with EPN can be simple, radical or laparoscopic.
© 2010 THE AUTHORS. BJU INTERNATIONAL © 2010 BJU INTERNATIONAL.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20840327     DOI: 10.1111/j.1464-410X.2010.09660.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  62 in total

1.  Coexistence of emphysematous cystitis and bilateral emphysematous pyelonephritis: a case report and review of the literature.

Authors:  Venice Chávez-Valencia; Citlalli Orizaga-de-La-Cruz; Omar Aguilar-Bixano; Francisco Alejandro Lagunas-Rangel
Journal:  CEN Case Rep       Date:  2020-04-23

2.  Emphysematous pyelonephritis: Changing trend of clinical spectrum, pathogenesis, management and outcome.

Authors:  Ashok Kumar Sokhal; Manoj Kumar; Bimalesh Purkait; Ankur Jhanwar; Kawaljit Singh; Ankur Bansal; Satyanarayan Sankhwar
Journal:  Turk J Urol       Date:  2017-01-27

3.  Concealed diagnosis of duodenal perforation in a patient with emphysematous pyelonephritis: the dilemma of air in the right perirenal space.

Authors:  Saqib Mehdi; Vishwajeet Singh; Rahul Janak Sinha; Siddharth Pandey
Journal:  BMJ Case Rep       Date:  2019-02-13

4.  Successful management of bilateral emphysematous pyelonephritis with abscess formation in a chronic hemodialysis patient: a case report.

Authors:  Ryuji Suzuki; Takehiko Abe; Hiroji Uchida; Kazuhiko Niikura
Journal:  CEN Case Rep       Date:  2014-10-18

5.  Emphysematous pyelonephritis: a case report.

Authors:  V Rafailidis; V Karadimou; C Liouliakis; D Kougioumtzoglou
Journal:  Hippokratia       Date:  2013-10       Impact factor: 0.471

6.  Role of Conservative Management in Emphysematous Pyelonephritis - A Retrospective Study.

Authors:  Sholay Meitei Kangjam; Keshorjit Singh Irom; Ibomcha Singh Khumallambam; Rajendra Singh Sinam
Journal:  J Clin Diagn Res       Date:  2015-11-01

7.  Risk of SOFA Deterioration in Conservative Treatment for Emphysematous Pyelonephritis: Pitfalls of Current Trends in Therapeutics from Multicenter Clinical Experience.

Authors:  Michinobu Ozawa; Osamu Ichiyanagi; Suguru Fujita; Sei Naito; Hiroki Fukuhara; Shinta Suenaga; Satoshi Takai; Takafumi Narisawa; Noriyuki Hosoya; Tatsuya Ishii; Takuya Yamanobe; Akinori Muto; Hitoshi Suzuki; Hayato Nishida; Tomoyuki Kato; Norihiko Tsuchiya
Journal:  Curr Urol       Date:  2019-05-10

8.  Comparative study of emphysematous pyelonephritis and pyelonephritis in type 2 diabetes: a single-centre experience.

Authors:  Tauseef Nabi; Nadeema Rafiq; Mohammad Hifz Ur Rahman; Shahnawaz Rasool; Nayeem U Din Wani
Journal:  J Diabetes Metab Disord       Date:  2020-09-28

9.  Emphysematous pyelonephritis in an infant from Sokoto, north-western Nigeria.

Authors:  Fatima B Jiya; Paul K Ibitoye; Nma M Jiya; Maryam Amodu-Sanni; Yahaya Mohammed; Dada M Aquib; Lukman K Coker
Journal:  Afr J Lab Med       Date:  2021-04-26

10.  Concurrent Bilateral Emphysematous Pyelonephritis and Emphysematous Cystitis: A Case Report of Glomerulonephritis Severe Complication.

Authors:  Michał Godzisz; Przemysław Mitura; Damian Widz; Damian Sudoł; Iga Kuliniec; Krzysztof Bar
Journal:  Res Rep Urol       Date:  2021-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.